London 2014 Registration Visa Letters Programme Satellite Meetings Glaucoma Day 2014 Exhibition Hotel Booking Virtual Exhibition Star Alliance
london escrs

Course handouts are now available
Click here

Come to London


WATCH to find out why

Site updates:

Programme Updates. Programme Overview and - Video Symposium on Challenging Cases now available.


Search Abstracts by author or title
(results will display both Free Papers & Poster)

XEN gel stent implantation to control intraocular pressure combined with cataract surgery: short and mid-term outcomes

Poster Details

First Author: H.Morbelli SPAIN

Co Author(s):    J. Rodríguez-Prats   P. Taña           

Abstract Details


The management of uncontrolled intraocular pressure in open-angle glaucoma patients by trabeculectomy requires substantial dissection of ocular tissues and therefore, this technique has a high complication rate. A new, less invasive technique, based on an ab interno-implanted gel stent, has recently been developed. The aim of this presentation is to show our outcomes after XEN gel stent implantation for lowering intraocular pressure (IOP), combined with cataract surgery performed with a femtosecond laser platform.


Oftalvist Ophthalmology Clinic, Alicante, Spain. Oftalvist Group.


15 patients underwent XEN gel stent implantation combined with femtosecond laser cataract surgery. The study was performed in accordance with the guidelines of the Declaration of Helsinki. All subjects were over 18 years of age and signed informed consent. All patients were undergone according to the same surgical protocol, performed by the same surgeon.


The features of XEN implant and its implantation technique are described. Moreover, the advantages, disadvantages and complications during the cataract and glaucoma procedures combination are discussed.


The XEN gel stent is minimally invasive and minimizes post-surgery complications. Further studies with this novel technique are necessary but it seems safe and effective combined with cataract surgery performed with a femtosecond laser platform. FINANCIAL INTEREST: NONE

Back to Poster listing